SEC Filing Summary: Nanobiotix S.A. (6-K)
Business Context and Reporting Period
This filing is a Form 6-K reporting individual transactions by persons discharging managerial responsibilities or closely associated persons, as required under Article L.621-18-2 of the French Monetary and Financial Code. The notifications were received on July 2, 2025, covering transactions executed on June 27, 2025.
Key Financial Metrics and Transaction Details
The filing details the gratuitous allocation of shares to four senior executives. No revenue, profit, cash flow, or debt metrics are provided in this specific document.
| Executive | Role | Transaction Type | Volume (Shares) | Unit Price (EUR) | Total Value (EUR) |
|---|---|---|---|---|---|
| Anne-Juliette Hermant | Directrice des Ressources Humaines | Gratuitous Allocation | 66,708 | 0.00 | 0.00 |
| Anne-Sophie Lariviere | Vice-présidente Stratégie & Excellence opérationnelle | Gratuitous Allocation | 40,000 | 0.00 | 0.00 |
| Laurent Levy | Chief Executive Officer | Gratuitous Allocation | 400,232 | 0.00 | 0.00 |
| Bartholomeus Van Rhijn | Directeur Financier et du Business Développement | Gratuitous Allocation | 130,780 | 0.00 | 0.00 |
| Total | - | - | 637,720 | 0.00 | 0.00 |
Note: The opening share price on the transaction date was reported as €4.04.
Material Changes and Unusual Items
The filing reports a significant increase in share ownership for the named executives through a non-cash transaction. These allocations are linked to stock option programs or performance share plans. The transactions occurred off-exchange ("Hors plateforme de négociation").
Guidance, Outlook, and Risks
The filing text does not provide financial guidance, management commentary on future outlook, or specific risk factors beyond the standard regulatory disclaimer that the notification has not been controlled by the AMF (Autorité des Marchés Financiers) and is the sole responsibility of the declarant.
Investor Verification Checklist
- Verify the total number of shares issued (637,720) against the company's authorized share capital and dilution impact.
- Confirm the vesting schedules and performance conditions attached to these gratuitous allocations in the company's equity incentive plan documents.
- Review the company's latest financial statements to assess the cash burn rate relative to the equity-based compensation expense.
- Check for any subsequent filings regarding the sale or transfer of these newly allocated shares.